Polar Capital’s Verona Pharma VRNA Stock Holding History

Polar Capital’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$6.24M	Buy	+1,000,000	New	+$6.91M	0.05%	201
2019 Q4	–	Sell	-100,000	Closed	-$457K	–	310
2019 Q3	$457K	Hold	100,000	–	–	﹤0.01%	269
2019 Q2	$510K	Hold	100,000	–	–	﹤0.01%	271
2019 Q1	$650K	Hold	100,000	–	–	0.01%	253
2018 Q4	$965K	Hold	100,000	–	–	0.01%	241
2018 Q3	$1.25M	Hold	100,000	–	–	0.01%	255
2018 Q2	$1.37K	Hold	100,000	–	–	0.01%	245
2018 Q1	$2M	Buy	100,000 +4,851	+5%	+$70.1K	0.02%	243
2017 Q4	$1.13M	Buy	95,149 +19,232	+25%	+$250K	0.01%	242
2017 Q3	$1.17M	Buy	+75,917	New	+$1M	0.01%	234

Other funds holding VRNA

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return